Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Sara A. Hurvitz Fabrice Andre; Zefei Jiang; Zhimin Shao; Silvia P Neciosup; Max S Mano; Ling-Min Tseng; Qingyuan Zhang; Kunwei Shen; Donggeng Liu; Lydia M Dreosti; Jifeng Feng; Howard A Burris; Masakazu Toi; Marc E Buyse; David Cabaribere; Mary-Ann Lindsay; Tiffany Kunz; Shantha Rao; Lida B Pacaud; Tetiana Taran; Dennis Slamon; Annual CTRC-AACR San Antonio Breast Cancer Symposium (37. 2014 San Antonio, TX)
Cancer Research Baltimore v. 75, abst. S6-01, May, 2015Baltimore 2015
Acesso online. A biblioteca também possui exemplares impressos.